The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization of a treatment for pseudobulbar affect (PBA) in adults (Nuedexta, Avanir Pharmaceuticals Inc).
The treatment, a combination of dextromethorphan hydrobromide and quinidine sulphate, is already approved for this indication by the United States Food and Drug Administration (FDA).
Ecco il link al prodotto:
Nessun commento:
Posta un commento